SCM Lifescience Co., Ltd. (KOSDAQ:298060)

Market Cap	37.31B +38.3%
Revenue (ttm)	1.54B +53.7%
Net Income	-8.24B
EPS	-362.75
Shares Out	44.20M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	66,449
Average Volume	149,415
Open	855.00
Previous Close	855.00
Day's Range	824.00 - 855.00
52-Week Range	777.00 - 1,675.00
Beta	0.75
RSI	46.11
Earnings Date	n/a

About SCM Lifescience

SCM Lifescience Co., Ltd. operates as a stem cell therapy company in South Korea. It develops SCM-AGH, a treatment for moderate to severe acute pancreatitis and moderate to severe atopic dermatitis, as well as chronic graft versus host disease; and Iroro Deerscalp, a toothbrush cosmetic for hair loss relief. The company was founded in 2014 and is headquartered in Incheon, South Korea.

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2014
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 298060

Financial Performance

In 2024, SCM Lifescience's revenue was 824.80 million, an increase of 18.56% compared to the previous year's 695.70 million. Losses were -12.38 billion, -48.35% less than in 2023.